Regeneron Exceeds First-Quarter Earnings Estimates with Dupixent Growth
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported first-quarter results that exceeded expectations, driven by strong performance from its Dupixent collaboration with Sanofi. Revenue reached $3.6 billion, up 19% year-over-year, and shares rose 1.4% following the announcement. However, the company faces margin pressures due to a production disruption at its Limerick facility.
Topics: Dupixent Earnings Revenue Growth Share Buybacks Stock Performance